Ionis Pharmaceuticals affiliate Akcea Therapeutics (NASDAQ:AKCA) initiates a Phase 2b clinical trial assessing AKCEA-APOCIII-Lrx in patients with high triglycerides (hypertriglyceridemia) and established cardiovascular (CV) disease. The study will evaluate different doses and dosing frequencies to inform a Phase 3 CV outcomes trial (CVOT).
Under a January 2017 agreement, Novartis (NYSE:NVS) has the option to acquire the rights to the product after the study is finished. If it elects to do so, it will be responsible for conducting the Phase 3 CVOT, global development and co-commercialization activities.
AKCEA-APOCIII-Lrx is an antisense drug that inhibits the production of apolipoprotein C-III (ApoC-III), a component of very low density lipoprotein, which is associated with increased risk of coronary heart disease.
Previously: Ionis Pharma's AKCEA-APOCIII-Lrx shows treatment effect in Phase 1/2a study (Oct. 31, 2017)
Now read: 2018 Healthcare And Biotech Outlook »
Subscribe for full text news in your inbox